Skip to main content
Premium Trial:

Request an Annual Quote

Horizon CombinatoRx to Profile Oncology Asset for Pharma Firm

NEW YORK(GenomeWeb) – Horizon Discovery today said that its CombinatoRx division has inked a contract with an unnamed "top 10" pharmaceutical firm to profile a lead oncology asset. 

Horizon CombinatoRx will be paid $750,000 for work completed within a five-month period, it said. The company provides its partners access to the combination high-throughput screening platform and Chalice analytics software for the screening and analysis of thousands of complementary drug combinations. Horizon acquired CombinatoRx in June for $8 million.

Last month, Horizon CombinatoRx announced a similar contract with another undisclosed pharma firm. In July, it signed a contract with Otsuka Pharmaceutical Development and Commercialization to perform in vitro cell line screening of certain OPDC candidates in development. 

The Scan

Booster Push

New data shows a decline in SARS-CoV-2 vaccine efficacy over time, which the New York Times says Pfizer is using to argue its case for a booster, even as the lower efficacy remains high.

With Help from Mr. Fluffington, PurrhD

Cats could make good study animals for genetic research, the University of Missouri's Leslie Lyons tells the Atlantic.

Man Charged With Threatening to Harm Fauci, Collins

The Hill reports that Thomas Patrick Connally, Jr., was charged with making threats against federal officials.

Nature Papers Present Approach to Find Natural Products, Method to ID Cancer Driver Mutations, More

In Nature this week: combination of cryogenic electron microscopy with genome mining helps uncover natural products, driver mutations in cancer, and more.